Developer docs
API playgroundTry for free, no card

Search company profiles

SPD Swiss Precision Diagnostics

Full company profile

uuid000bk7g

Namestring
SPD Swiss Precision Diagnostics
Legal namestring
SPD Swiss Precision Diagnostics GmbH
Company typeenum
Private
Founded yearint
2007
Descriptiontext

SPD Swiss Precision Diagnostics GmbH (SPD) is a Geneva-headquartered joint venture formed in 2007 between Procter & Gamble and Abbott, operating under the globally recognized Clearblue brand as a category leader in home reproductive diagnostics. The company researches, designs, and markets consumer diagnostic products for women navigating pregnancy, fertility, and menopause, including digital pregnancy tests with weeks indicator (97% agreement with ultrasound dating), a dual-hormone (E3G + LH) Advanced Fertility Monitor that increases chance of conceiving by up to 89% in the first two cycles, and the Clearblue Menopause Stage Indicator (US only) that combines five serial FSH readings with cycle history through a companion app. Core technology is built on regulated lateral flow immunoassay chemistry combined with embedded digital electronics, with the portfolio protected by 5 granted US utility patents, 2 pending applications, and 12 US design patents.

The business operates as a consumer health products company with a B2C distribution model spanning Europe, North America, and Asia Pacific. Products reach end consumers through three channels: physical retail (pharmacies, supermarkets, and major retail chains), e-commerce and online retail (the fastest-growing channel at 25-30% annual growth in key markets), and regional import/distribution in import-dependent markets such as Mexico. Revenue mechanics combine unit sales of single-use pregnancy and ovulation tests with a razor/blade dynamic in the fertility monitor line, where the handheld reader requires recurring purchase of proprietary disposable test sticks. The company has legal entities in Switzerland (SPD Swiss Precision Diagnostics GmbH), the United Kingdom (SPD Development Company Ltd., housing the Clearblue Innovation Centre R&D function in Bedford), and a sales office in Shanghai (SPD Trading Co. Ltd.) for the China market. SPD is regulated as an in vitro medical device manufacturer under FDA, European IVDR, Health Canada, Australian TGA, Japan PMDA, and Brazil ANVISA frameworks, with MDSAP single-audit compliance.

Short descriptiontext

SPD Swiss Precision Diagnostics is a Geneva-based 50/50 joint venture between Procter & Gamble and Abbott, formed in 2007 and operating under the Clearblue brand to research, design, and market home pregnancy tests, ovulation and fertility monitors, and (in the US) a menopause stage indicator for women globally.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersBedford, United Kingdom
HQ citystring
Bedford
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
home pregnancy tests, ovulation fertility tests, consumer diagnostic products, rapid diagnostic technology, menopause stage indicators
Industry2 codes
PRIMARYHLAHAOAK
Home-Use & OTC Rapid Self-Tests (Consumer POCT kits)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Point-of-Care Testing (POCT) & Rapid Diagnostics
SECONDARYCRADAMAK
Personal Medical Devices & Home Diagnostics (Thermometers, Blood Pressure Monitors, Glucose Meters, Rapid Tests)
Consumer Products & Retail/Consumer Packaged Goods (CPG) Manufacturing & Brands/Health & Hygiene OTC Consumer Goods (First Aid, Oral Care, Personal Health)
NAICS code2 codes
  • In-Vitro Diagnostic Substance Manufacturing325413
  • Navigational, Measuring, Electromedical, and Control Instruments Manufacturing3345
SIC code2 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Surgical & Medical Instruments & Apparatus3841
Product category
Consumer Diagnostics
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Consumer Diagnostic Hardware Sales
TypeHardware Sales
Description

Sale of home pregnancy tests, ovulation/fertility tests, and menopause stage indicators as consumer medical devices through retail and e-commerce channels worldwide.

swissprecisiondiagnostics.com
2Advanced Fertility Monitor System
TypeHardware Sales
Description

Sale of handheld fertility monitor devices plus recurring revenue from disposable test sticks required for each testing cycle

swissprecisiondiagnostics.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Supply Chain, Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure
GTM typeB2C
B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1Clearblue
Description

World-renowned brand for accurate home pregnancy and fertility tests, known for accuracy, reliability, and simplicity. The brand has earned a global reputation and was the first to introduce one-step pregnancy test, one minute test, sample sufficiency indicator, digitally displayed results, and Weeks Indicator feature.

swissprecisiondiagnostics.com
Core offering1 text field

SPD Swiss Precision Diagnostics manufactures and markets advanced consumer diagnostic products under the Clearblue brand, including home pregnancy tests, ovulation and fertility tests, and a menopause stage indicator. The company combines lateral flow rapid diagnostic technology with digital features and sells globally through retail pharmacies and e-commerce channels.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Clearblue Advanced Fertility Monitor increases chance of conceiving by up to 89% in first two cycles of use
+2 more records
Product overview1 text field

SPD Swiss Precision Diagnostics is a joint venture between Procter & Gamble and Abbott formed in 2007, operating under the Clearblue® brand as a world leader in consumer diagnostic products. The company's product portfolio encompasses three core product lines: (1) Pregnancy Tests including Clearblue® Digital Ultra Early, Ultra Early, Digital Early Detection, Rapid Detection, Flip & Click, and Pregnancy Test with Weeks Indicator; (2) Fertility/Ovulation Tests including Clearblue® Advanced Fertility Monitor, Advanced Digital Ovulation Test, and Digital Ovulation Test; and (3) Menopause Products including Clearblue® Menopause Stage Indicator. The company also offers a companion app for the Menopause Stage Indicator enabling cycle and symptom tracking with personalized reporting. Products are regulated under IVDR (Europe), FDA (US), Health Canada, Australian TGA, Japan's PMDA, and Brazil's ANVISA, with headquarters in Geneva, Switzerland and innovation center in Bedford, UK.

Product and service1 record
1Clearblue Digital Ultra Early Pregnancy Test
Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
1British IVD Association (BIVDA)
Strategic tierMinorTypeOthersAnnounced on2024-01-01
Description

National industry association for manufacturers and distributors of in vitro diagnostic products in the UK. Clearblue is a member supporting the industry and regulatory advocacy.

swissprecisiondiagnostics.com
Strategic tierMinorTypeOthersAnnounced on2024-01-01
Description

European trade association for medical technology. Clearblue is a member supporting regulatory advocacy and industry standards in diagnostic devices.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-01-01
Description

Community organization for women seeking information and connection about the menopause journey. Partnership supports education and awareness for women transitioning through menopause, aligning with Clearblue's menopause product portfolio expansion.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2017-01-01
Description

US-based charity working in prenatal health, premature birth prevention, and infant health. SPD supports through research and education initiatives in reproductive health. March of Dimes educates the public and medical professionals about best practices, supports lifesaving research, and advocates for mums and babies.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2017-01-01
Description

Mobile app connecting blind and low vision users with sighted volunteers and company representatives through live video connection. Partnership enables blind women to be the first to receive their Clearblue pregnancy or ovulation test result independently through the app's accessibility platform.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2007-01-01
Description

P&G is one of two joint venture partners forming SPD Swiss Precision Diagnostics. P&G contributes major consumer goods expertise, household brand reach, and consumer marketing capabilities. The joint venture combines P&G's consumer goods strengths with Abbott's diagnostic technology to bring consumer diagnostic innovation to market globally.

7Abbott
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2007-01-01
Description

Abbott is one of two joint venture partners forming SPD Swiss Precision Diagnostics. Abbott creates breakthrough products in diagnostics, medical devices, nutrition, and pharmaceuticals. The joint venture combines Abbott's diagnostic technology expertise with P&G's consumer marketing to deliver home diagnostic products.

swissprecisiondiagnostics.com
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Church & Dwight markets the First Response brand of home pregnancy and ovulation tests in North America, making it the most direct branded competitor to Clearblue in the same consumer POCT category with overlapping retail placement and pricing tiers.

TypeDirect peer
Description

Wondfo is one of the world's largest manufacturers of lateral flow rapid diagnostic tests including pregnancy and fertility kits, serving both consumer and clinical channels globally, with a particularly strong China distribution footprint that competes with SPD's own Chinese sales presence.

3Easy@Home (Clinical Genomics)
TypeDirect peer
Description

Easy@Home sells home pregnancy and ovulation tests direct-to-consumer through e-commerce marketplaces, competing head-to-head on price and convenience in the same consumer POCT category Clearblue dominates through retail.

TypeDirect peer
Description

Prestige markets the E.P.T. home pregnancy test brand, a long-standing direct competitor to Clearblue in the US consumer pregnancy testing category with comparable retail positioning and product positioning around accuracy and ease of use.

TypeBroad incumbent
Description

QuidelOrtho is a major in vitro diagnostics manufacturer producing a broad portfolio of rapid lateral flow and immunoassay tests across clinical and consumer channels, providing benchmark scale and R&D capabilities across diagnostic categories that overlap with SPD's lateral flow technology base.

TypeBroad incumbent
Description

Hologic is a women's health-focused diagnostic and medical device company with adjacent franchises in reproductive health (e.g., prenatal screening, NovaBay), making it a broader incumbent in women's reproductive diagnostics that overlaps with SPD's core customer population though via clinical rather than consumer channels.

TypeBroad incumbent
Description

bioMérieux is a large in vitro diagnostics company with broad portfolio capabilities in clinical diagnostics and industrial microbiology, providing reference scale and regulatory infrastructure comparable to what Abbott contributes through the SPD joint venture.

TypeRegional player
Description

Gerhardt's Prega News is a leading home pregnancy test brand in Germany and parts of Europe, competing directly with Clearblue in regional retail channels and offering similar lateral flow technology with strong pharmacy distribution in the DACH region.

TypeEmerging player
Description

Ava sells a connected fertility tracking bracelet that predicts fertile windows via physiological signals, representing a tech-forward emerging alternative to ovulation test strips and competing for the same 'trying to conceive' consumer segment Clearblue's Advanced Fertility Monitor targets.

TypeEmerging player
Description

Mira offers a connected at-home hormone tracker that quantitatively measures E3G, LH, and other fertility hormones via disposable test wands and an app, positioning it as an emerging digital alternative to Clearblue's fertility monitor with a recurring-stick revenue model directly analogous to SPD's flagship product.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

SPD Swiss Precision Diagnostics

Consumer Diagnosticsswissprecisiondiagnostics.com

SPD Swiss Precision Diagnostics is a Geneva-based 50/50 joint venture between Procter & Gamble and Abbott, formed in 2007 and operating under the Clearblue brand to research, design, and market home pregnancy tests, ovulation and fertility monitors, and (in the US) a menopause stage indicator for women globally.

What SPD Swiss Precision Diagnostics does

SPD Swiss Precision Diagnostics GmbH (SPD) is a Geneva-headquartered joint venture formed in 2007 between Procter & Gamble and Abbott, operating under the globally recognized Clearblue brand as a category leader in home reproductive diagnostics. The company researches, designs, and markets consumer diagnostic products for women navigating pregnancy, fertility, and menopause, including digital pregnancy tests with weeks indicator (97% agreement with ultrasound dating), a dual-hormone (E3G + LH) Advanced Fertility Monitor that increases chance of conceiving by up to 89% in the first two cycles, and the Clearblue Menopause Stage Indicator (US only) that combines five serial FSH readings with cycle history through a companion app. Core technology is built on regulated lateral flow immunoassay chemistry combined with embedded digital electronics, with the portfolio protected by 5 granted US utility patents, 2 pending applications, and 12 US design patents.

The business operates as a consumer health products company with a B2C distribution model spanning Europe, North America, and Asia Pacific. Products reach end consumers through three channels: physical retail (pharmacies, supermarkets, and major retail chains), e-commerce and online retail (the fastest-growing channel at 25-30% annual growth in key markets), and regional import/distribution in import-dependent markets such as Mexico. Revenue mechanics combine unit sales of single-use pregnancy and ovulation tests with a razor/blade dynamic in the fertility monitor line, where the handheld reader requires recurring purchase of proprietary disposable test sticks. The company has legal entities in Switzerland (SPD Swiss Precision Diagnostics GmbH), the United Kingdom (SPD Development Company Ltd., housing the Clearblue Innovation Centre R&D function in Bedford), and a sales office in Shanghai (SPD Trading Co. Ltd.) for the China market. SPD is regulated as an in vitro medical device manufacturer under FDA, European IVDR, Health Canada, Australian TGA, Japan PMDA, and Brazil ANVISA frameworks, with MDSAP single-audit compliance.

SPD Swiss Precision Diagnostics firmographics

Firmographics
Name
SPD Swiss Precision Diagnostics
Legal name
SPD Swiss Precision Diagnostics GmbH
Website
https://swissprecisiondiagnostics.com
Company type
Private
Founded year
2007
Operating status
Operating
Headcount range
101–250 employees
Short description
SPD Swiss Precision Diagnostics is a Geneva-based 50/50 joint venture between Procter & Gamble and Abbott, formed in 2007 and operating under the Clearblue brand to research, design, and market home pregnancy tests, ovulation and fertility monitors, and (in the US) a menopause stage indicator for women globally.
Ownership category
akta.pro rank

SPD Swiss Precision Diagnostics industry classification

Industry
Product category
Consumer Diagnostics
NAICS
In-Vitro Diagnostic Substance Manufacturing (325413), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (3345)
SIC
In Vitro & In Vivo Diagnostic Substances (2835), Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAHAOAK
Home-Use & OTC Rapid Self-Tests (Consumer POCT kits)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Point-of-Care Testing (POCT) & Rapid Diagnostics
SECONDARYCRADAMAK
Personal Medical Devices & Home Diagnostics (Thermometers, Blood Pressure Monitors, Glucose Meters, Rapid Tests)
Consumer Products & Retail/Consumer Packaged Goods (CPG) Manufacturing & Brands/Health & Hygiene OTC Consumer Goods (First Aid, Oral Care, Personal Health)

Keywords

  • Home pregnancy tests
  • Ovulation fertility tests
  • Consumer diagnostic products
  • Rapid diagnostic technology
  • Menopause stage indicators

Where SPD Swiss Precision Diagnostics is headquartered

Location

Headquarters

HQ city
Bedford
HQ country
United Kingdom
HQ region
Europe

Offices3 records

Markets served

SPD Swiss Precision Diagnostics business model

Business model
GTM type
B2C
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure

Revenue model

  1. Consumer Diagnostic Hardware Sales: Sale of home pregnancy tests, ovulation/fertility tests, and menopause stage indicators as consumer medical devices through retail and e-commerce channels worldwide.
  2. Advanced Fertility Monitor System: Sale of handheld fertility monitor devices plus recurring revenue from disposable test sticks required for each testing cycle

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

SPD Swiss Precision Diagnostics product offering

Product offering

Core offering

SPD Swiss Precision Diagnostics manufactures and markets advanced consumer diagnostic products under the Clearblue brand, including home pregnancy tests, ovulation and fertility tests, and a menopause stage indicator. The company combines lateral flow rapid diagnostic technology with digital features and sells globally through retail pharmacies and e-commerce channels.

Product overview

SPD Swiss Precision Diagnostics is a joint venture between Procter & Gamble and Abbott formed in 2007, operating under the Clearblue® brand as a world leader in consumer diagnostic products. The company's product portfolio encompasses three core product lines: (1) Pregnancy Tests including Clearblue® Digital Ultra Early, Ultra Early, Digital Early Detection, Rapid Detection, Flip & Click, and Pregnancy Test with Weeks Indicator; (2) Fertility/Ovulation Tests including Clearblue® Advanced Fertility Monitor, Advanced Digital Ovulation Test, and Digital Ovulation Test; and (3) Menopause Products including Clearblue® Menopause Stage Indicator. The company also offers a companion app for the Menopause Stage Indicator enabling cycle and symptom tracking with personalized reporting. Products are regulated under IVDR (Europe), FDA (US), Health Canada, Australian TGA, Japan's PMDA, and Brazil's ANVISA, with headquarters in Geneva, Switzerland and innovation center in Bedford, UK.

Differentiator

Problem solved

Functional benefit

Brands

  • Clearblue: World-renowned brand for accurate home pregnancy and fertility tests, known for accuracy, reliability, and simplicity. The brand has earned a global reputation and was the first to introduce one-step pregnancy test, one minute test, sample sufficiency indicator, digitally displayed results, and Weeks Indicator feature.

Products and services

  • Clearblue Digital Ultra Early Pregnancy Test

Quantifiable outcome

  • Clearblue Advanced Fertility Monitor increases chance of conceiving by up to 89% in first two cycles of use
  • +2 more outcomes

Companies that use SPD Swiss Precision Diagnostics

Customer profile

Named customers3 records

Segments3 records

Ideal customer profiles3 records

SPD Swiss Precision Diagnostics technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature7 records

SPD Swiss Precision Diagnostics partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered minor, core and flagship.

  • British IVD Association (BIVDA)minorOthers · 1 January 2024National industry association for manufacturers and distributors of in vitro diagnostic products in the UK. Clearblue is a member supporting the industry and regulatory advocacy.
  • MedTech EuropeminorOthers · 1 January 2024European trade association for medical technology. Clearblue is a member supporting regulatory advocacy and industry standards in diagnostic devices.
  • National Menopause FoundationcoreStrategic or Co-development Partner · 1 January 2023Community organization for women seeking information and connection about the menopause journey. Partnership supports education and awareness for women transitioning through menopause, aligning with Clearblue's menopause product portfolio expansion.
  • March of DimescoreStrategic or Co-development Partner · 1 January 2017US-based charity working in prenatal health, premature birth prevention, and infant health. SPD supports through research and education initiatives in reproductive health. March of Dimes educates the public and medical professionals about best practices, supports lifesaving research, and advocates for mums and babies.
  • Be My EyescoreTechnology or Integration · 1 January 2017Mobile app connecting blind and low vision users with sighted volunteers and company representatives through live video connection. Partnership enables blind women to be the first to receive their Clearblue pregnancy or ovulation test result independently through the app's accessibility platform.
  • Procter & Gamble (P&G)flagshipStrategic or Co-development Partner · 1 January 2007P&G is one of two joint venture partners forming SPD Swiss Precision Diagnostics. P&G contributes major consumer goods expertise, household brand reach, and consumer marketing capabilities. The joint venture combines P&G's consumer goods strengths with Abbott's diagnostic technology to bring consumer diagnostic innovation to market globally.
  • AbbottflagshipStrategic or Co-development Partner · 1 January 2007Abbott is one of two joint venture partners forming SPD Swiss Precision Diagnostics. Abbott creates breakthrough products in diagnostics, medical devices, nutrition, and pharmaceuticals. The joint venture combines Abbott's diagnostic technology expertise with P&G's consumer marketing to deliver home diagnostic products.

Scale indicators5 records

Recent moves7 records

Expansion highlights6 records

SPD Swiss Precision Diagnostics competitors and assessment

Company assessment

Direct peers

  • Church & Dwight (First Response): Church & Dwight markets the First Response brand of home pregnancy and ovulation tests in North America, making it the most direct branded competitor to Clearblue in the same consumer POCT category with overlapping retail placement and pricing tiers.
  • Wondfo: Wondfo is one of the world's largest manufacturers of lateral flow rapid diagnostic tests including pregnancy and fertility kits, serving both consumer and clinical channels globally, with a particularly strong China distribution footprint that competes with SPD's own Chinese sales presence.
  • Easy@Home (Clinical Genomics): Easy@Home sells home pregnancy and ovulation tests direct-to-consumer through e-commerce marketplaces, competing head-to-head on price and convenience in the same consumer POCT category Clearblue dominates through retail.
  • Prestige Consumer Healthcare (E.P.T.): Prestige markets the E.P.T. home pregnancy test brand, a long-standing direct competitor to Clearblue in the US consumer pregnancy testing category with comparable retail positioning and product positioning around accuracy and ease of use.

Broad incumbents

  • QuidelOrtho: QuidelOrtho is a major in vitro diagnostics manufacturer producing a broad portfolio of rapid lateral flow and immunoassay tests across clinical and consumer channels, providing benchmark scale and R&D capabilities across diagnostic categories that overlap with SPD's lateral flow technology base.
  • Hologic: Hologic is a women's health-focused diagnostic and medical device company with adjacent franchises in reproductive health (e.g., prenatal screening, NovaBay), making it a broader incumbent in women's reproductive diagnostics that overlaps with SPD's core customer population though via clinical rather than consumer channels.
  • bioMérieux: bioMérieux is a large in vitro diagnostics company with broad portfolio capabilities in clinical diagnostics and industrial microbiology, providing reference scale and regulatory infrastructure comparable to what Abbott contributes through the SPD joint venture.

Regional players

  • Avalun (Gerhardt Pharma - Prega News): Gerhardt's Prega News is a leading home pregnancy test brand in Germany and parts of Europe, competing directly with Clearblue in regional retail channels and offering similar lateral flow technology with strong pharmacy distribution in the DACH region.

Emerging players

  • Ava (Ava Science): Ava sells a connected fertility tracking bracelet that predicts fertile windows via physiological signals, representing a tech-forward emerging alternative to ovulation test strips and competing for the same 'trying to conceive' consumer segment Clearblue's Advanced Fertility Monitor targets.
  • Mira (Quanovate): Mira offers a connected at-home hormone tracker that quantitatively measures E3G, LH, and other fertility hormones via disposable test wands and an app, positioning it as an emerging digital alternative to Clearblue's fertility monitor with a recurring-stick revenue model directly analogous to SPD's flagship product.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

SPD Swiss Precision Diagnostics social profiles

Digital presence

SPD Swiss Precision Diagnostics compliance and trust

Trust signal

Compliance4 records

SPD Swiss Precision Diagnostics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

SPD Swiss Precision Diagnostics leadership team

Management profile

Number of profiles

Profiles1 record

SPD Swiss Precision Diagnostics funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

SPD Swiss Precision Diagnostics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SPD Swiss Precision Diagnostics

What does SPD Swiss Precision Diagnostics do?

SPD Swiss Precision Diagnostics manufactures and markets advanced consumer diagnostic products under the Clearblue brand, including home pregnancy tests, ovulation and fertility tests, and a menopause stage indicator. The company combines lateral flow rapid diagnostic technology with digital features and sells globally through retail pharmacies and e-commerce channels.

Is SPD Swiss Precision Diagnostics a public or private company?

SPD Swiss Precision Diagnostics is a private company. It is classified as corporate owned and is currently operating.

When was SPD Swiss Precision Diagnostics founded?

SPD Swiss Precision Diagnostics was founded in 2007. It employs 101 to 250 people.

Where is SPD Swiss Precision Diagnostics based?

SPD Swiss Precision Diagnostics is headquartered in Bedford, United Kingdom, in the Europe region.

How does SPD Swiss Precision Diagnostics make money?

Two revenue lines are on record. Consumer Diagnostic Hardware Sales are the primary driver. The others are advanced Fertility Monitor System.

Who are SPD Swiss Precision Diagnostics's main competitors?

Direct peers on record are Church & Dwight (First Response), Wondfo, Easy@Home (Clinical Genomics) and Prestige Consumer Healthcare (E.P.T.). Broad incumbents are QuidelOrtho, Hologic and bioMérieux. Avalun (Gerhardt Pharma - Prega News) is listed as a regional player. Emerging players are Ava (Ava Science) and Mira (Quanovate).

Does SPD Swiss Precision Diagnostics have an API?

No public API is recorded for SPD Swiss Precision Diagnostics.

What industry is SPD Swiss Precision Diagnostics in?

SPD Swiss Precision Diagnostics's product category is Consumer Diagnostics. Its primary akta.pro industry code is HLAHAOAK, Home-Use & OTC Rapid Self-Tests (Consumer POCT kits), with a secondary code of CRADAMAK, Personal Medical Devices & Home Diagnostics (Thermometers, Blood Pressure Monitors, Glucose Meters, Rapid Tests). Its NAICS code is 325413 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
IndexBoxReport - IndexBox - Prices, Size, Forecast, and CompaniesThis IndexBox market analysis report examines Russia's pregnancy and ovulation tests market, which is structurally import-dependent with over 60% of finished goods sourced from Europe and China, and is valued at a high tens-of-millions USD in 2026. E-commerce platforms led by Ozon and Wildberries have become the dominant retail channel, capturing 45-55% of consumer sales, while the market is projected to grow at a 5-7% CAGR through 2035, with ovulation tests as the fastest-growing segment at 10-15% annually. The competitive landscape features global brand owners SPD Swiss Precision Diagnostics (Clearblue) and Church & Dwight (First Response), alongside Russian players R-Pharm (Frautest, Evitest) and domestic assemblers, with import substitution policies and EAEU regulatory harmonization gradually incentivizing local assembly.LinkedInExploring the Dynamics of Fertility Monitors Market: Key Insights and Trends for 2033Verified Market Reports released a market analysis forecasting the global fertility monitors market to grow from USD 1.2 billion in 2024 to USD 2.5 billion by 2033, driven by technological advancements and shifting consumer expectations. The report highlights key industry players including Clearblue, Cyclotest, and SPD Swiss Precision Diagnostics while outlining strategic factors such as regulatory compliance and data privacy that influence buyer decisions.openPR.comOvulation Testing Kits Market Attracts Femtech Investment, Growing at 6.7% CAGR (2024-2031) |Top Companies 2025 - AdvaCare Pharma, Swiss Precision Diagnostics GmbHThe global ovulation testing kits market reached US$3.15 billion in 2023 and is projected to reach US$5.29 billion by 2031, a 6.7% CAGR. Growth is driven by rising fertility disorders like PCOS, with strategic moves including Ro's acquisition of Dadi and Inito's $6M funding.Market Research & Business IntelligenceFertility & Pregnancy Rapid Test Kits Market Forecast 2025-2035A market research report forecasts the global fertility pregnancy rapid test kits market will grow from USD 1.5 billion in 2024 to USD 2.49 billion by 2035, representing a CAGR of 4.5% during the forecast period. Key growth drivers include rising consumer preference for home-based testing, increasing focus on reproductive health, and digital integration such as Bluetooth-enabled devices and app-based features. The report identifies Abbott and Swiss Precision Diagnostic GmbH as actively innovating through facility expansion and product launches respectively, while emerging markets like India and China are projected to exhibit the highest CAGRs of 6.6% and 6.9%.openPR.comFertility Monitors Market Global Share, Trends, Business Boosting Strategies, Revenue, and Forecast 2024-2031 | Swiss Precision Diagnostics GmbH, UEBE Medical GmbH, Valley Electronics AG.DataM Intelligence forecasts the global fertility monitors market to grow at a 7.7% CAGR from 2024 to 2031. The market includes ovulation and hormone-based devices, with key players such as Swiss Precision Diagnostics and Valley Electronics. Growth is driven by rising reproductive health awareness and wearable technology.GlobeNewswirePrecision Diagnostics Market Size to Surpass USD 138.85 billion by 2028, exhibiting a CAGR of 12.6%The global precision diagnostics market is projected to reach USD 138.85 billion by 2028, up from USD 60.35 billion in 2021, at a CAGR of 12.6%. Growth is driven by rising cancer and neurological disorder cases, and higher healthcare spending. North America is expected to hold the largest regional share.PR NewswireBreaking Research Reveals That Not All Home Ovulation Tests Are Equally ReliableResearch presented at the AACC Annual Scientific Meeting indicates that two out of three digital home ovulation tests sold in the U.S. fail to accurately predict ovulation, with only one test demonstrating high reliability. The study found that while all tested devices measured luteinizing hormone levels correctly, design flaws such as insufficient test sticks or unreliable digital readers compromised their effectiveness. Swiss Precision Diagnostics, the manufacturer of the reliable Clearblue test, led the research highlighting these accuracy disparities.PR NewswireFertility Testing Devices Market Product, Mode of Purchase, and Region - Global Forecast to 2020A market research report by ReportLinker forecasts the global fertility testing devices market to reach USD 216.8 million by 2020, driven by declining fertility rates and increased investment in the Asia-Pacific region. The competitive landscape is dominated by SPD Swiss Precision Diagnostics GmbH, Church & Dwight Co., Inc., and Prestige Brands Holdings, which together held over 50% of the market share in 2014.